Sun Pharma Q3 Results: PAT advances 15% YoY to Rs 2,903 crore, beats estimates

Sun Pharma on Friday reported 15% year-on-year (YoY) to Rs 2,903 crore in the quarter ended December 2024. The company had incurred an exception item of Rs 316 crore in the reporting quarter.

The company has also declared an interim dividend of Rs 10.5 per share for the financial year 2024-25.

The profit was higher than the Street estimate of Rs 2,847 crore.


The record date for the proposed interim dividend is February 06 and the same will be paid on or before February 20. Revenue from operations in the reporting quarter rose 10% YoY to Rs 13,675 crore.

"Our performance in the quarter showed all-round improvement. Product sales in Global Specialty crossed 1/5th of overall sales. Our market share gain in India has been driven by industry-leading volume growth," said Dilip Shanghvi, Chairman and MD, Sun Pharma.

For the India formulation business, formulation sales rose 14% YoY to Rs 4,300 crore for Q3FY25 and accounted for about 32% of total consolidated sales.

Sun Pharma is ranked 1 and market share has increased from 7.8% to 8.2% in the over Rs 2.21 lakh crore Indian pharmaceutical market as per AIOCD AWACS MAT December 2024 report.

Formulation sales in the US fell marginally to $474 million for the third quarter. The same for Emerging markets rose 10% YoY to $277 million. In the rest of world (ROW) markets, sales jumped 21% YoY to $259 million in Q3FY25.
'Emerging Markets demonstrated strong performance in spite of currency challenges across geographies. All our businesses remain well positioned for future,” Sanghvi said.

External sales of API increased 22% YoY during the third quarter. For the first nine months, API sales were Rs 1596 crore. The company's API portfolio supports formulation business and API customers across geographies.

Consolidated R&D investments during the quarter were Rs 845 crore or 6.3% of sales.

On Friday, Sun Pharma shares closed 0.8% to Rs 1,752.85 on NSE.